Novavax Stock Return On Equity

NVAX Stock

USD 8.62 0.13 1.49%

Novavax fundamentals help investors to digest information that contributes to Novavax's financial success or failures. It also enables traders to predict the movement of Novavax Stock. The fundamental analysis module provides a way to measure Novavax's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novavax stock.

		Last Reported	Projected for Next Year
	Return On Equity	0.76	1.30

Return On Equity is likely to rise to 1.30 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novavax Company Return On Equity Analysis

Novavax's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Novavax Return On Equity

-8.98

Most of Novavax's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novavax is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Novavax Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Novavax is extremely important. It helps to project a fair market value of Novavax Stock properly, considering its historical fundamentals such as Return On Equity. Since Novavax's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novavax's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novavax's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Net Receivables	Intangible Assets	Short Term Debt	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.55	-0.89	-0.91	0.93	0.96	0.99	0.88	-0.46	0.63	-0.37	0.33	-0.98	0.87	0.77	0.96	-0.19	-0.62	0.47	0.94	-0.21	0.67	-0.41	-0.61	-0.78
Total Stockholder Equity	-0.55		0.42	0.79	-0.72	-0.76	-0.48	-0.4	0.35	0.0	0.15	-0.19	0.67	-0.74	-0.3	-0.46	0.71	0.99	-0.27	-0.68	0.13	-0.59	0.92	0.93	0.45
Net Debt	-0.89	0.42		0.69	-0.83	-0.83	-0.91	-0.76	0.23	-0.57	0.46	-0.03	0.87	-0.66	-0.85	-0.76	0.23	0.5	-0.18	-0.72	-0.02	-0.35	0.34	0.58	0.58
Retained Earnings	-0.91	0.79	0.69		-0.93	-0.97	-0.85	-0.77	0.5	-0.41	0.28	-0.33	0.95	-0.97	-0.54	-0.89	0.38	0.83	-0.52	-0.98	0.25	-0.79	0.68	0.78	0.77
Accounts Payable	0.93	-0.72	-0.83	-0.93		0.96	0.89	0.68	-0.41	0.6	-0.36	0.17	-0.96	0.93	0.57	0.87	-0.32	-0.77	0.39	0.91	-0.16	0.63	-0.59	-0.82	-0.71
Total Liab	0.96	-0.76	-0.83	-0.97	0.96		0.93	0.82	-0.47	0.49	-0.34	0.32	-0.98	0.93	0.69	0.9	-0.38	-0.81	0.46	0.96	-0.21	0.72	-0.63	-0.78	-0.76
Total Current Assets	0.99	-0.48	-0.91	-0.85	0.89	0.93		0.87	-0.45	0.67	-0.38	0.36	-0.95	0.8	0.83	0.93	-0.16	-0.57	0.47	0.89	-0.21	0.63	-0.32	-0.54	-0.76
Net Receivables	0.88	-0.4	-0.76	-0.77	0.68	0.82	0.87		-0.38	0.35	-0.43	0.31	-0.85	0.74	0.78	0.87	-0.15	-0.45	0.34	0.85	-0.14	0.6	-0.34	-0.36	-0.72
Intangible Assets	-0.46	0.35	0.23	0.5	-0.41	-0.47	-0.45	-0.38		-0.29	0.08	-0.53	0.44	-0.43	-0.29	-0.52	-0.12	0.36	-0.64	-0.53	0.53	-0.59	0.22	0.28	0.49
Short Term Debt	0.63	0.0	-0.57	-0.41	0.6	0.49	0.67	0.35	-0.29		-0.32	0.37	-0.55	0.41	0.42	0.63	0.17	-0.12	0.34	0.48	-0.14	0.42	0.28	-0.12	-0.56
Common Stock	-0.37	0.15	0.46	0.28	-0.36	-0.34	-0.38	-0.43	0.08	-0.32		0.09	0.43	-0.3	-0.33	-0.34	0.22	0.2	0.25	-0.32	-0.27	-0.14	0.05	0.17	0.63
Long Term Debt	0.33	-0.19	-0.03	-0.33	0.17	0.32	0.36	0.31	-0.53	0.37	0.09		-0.24	0.15	0.37	0.36	-0.08	-0.25	0.67	0.35	-0.47	0.68	0.11	0.03	-0.48
Treasury Stock	-0.98	0.67	0.87	0.95	-0.96	-0.98	-0.95	-0.85	0.44	-0.55	0.43	-0.24		-0.93	-0.7	-0.93	0.31	0.73	-0.39	-0.96	0.15	-0.67	0.54	0.72	0.77
Property Plant Equipment	0.87	-0.74	-0.66	-0.97	0.93	0.93	0.8	0.74	-0.43	0.41	-0.3	0.15	-0.93		0.41	0.89	-0.28	-0.75	0.4	0.96	-0.18	0.68	-0.67	-0.76	-0.69
Current Deferred Revenue	0.77	-0.3	-0.85	-0.54	0.57	0.69	0.83	0.78	-0.29	0.42	-0.33	0.37	-0.7	0.41		0.63	-0.23	-0.4	0.31	0.58	-0.12	0.41	-0.17	-0.33	-0.54
Good Will	0.96	-0.46	-0.76	-0.89	0.87	0.9	0.93	0.87	-0.52	0.63	-0.34	0.36	-0.93	0.89	0.63		-0.08	-0.52	0.51	0.96	-0.21	0.73	-0.33	-0.49	-0.81
Short Term Investments	-0.19	0.71	0.23	0.38	-0.32	-0.38	-0.16	-0.15	-0.12	0.17	0.22	-0.08	0.31	-0.28	-0.23	-0.08		0.73	0.25	-0.25	-0.42	-0.34	0.62	0.6	0.25
Net Tangible Assets	-0.62	0.99	0.5	0.83	-0.77	-0.81	-0.57	-0.45	0.36	-0.12	0.2	-0.25	0.73	-0.75	-0.4	-0.52	0.73		-0.29	-0.72	0.11	-0.65	0.86	0.93	0.53
Long Term Debt Total	0.47	-0.27	-0.18	-0.52	0.39	0.46	0.47	0.34	-0.64	0.34	0.25	0.67	-0.39	0.4	0.31	0.51	0.25	-0.29		0.53	-0.82	0.62	-0.15	-0.23	-0.47
Capital Surpluse	0.94	-0.68	-0.72	-0.98	0.91	0.96	0.89	0.85	-0.53	0.48	-0.32	0.35	-0.96	0.96	0.58	0.96	-0.25	-0.72	0.53		-0.26	0.79	-0.57	-0.67	-0.81
Deferred Long Term Liab	-0.21	0.13	-0.02	0.25	-0.16	-0.21	-0.21	-0.14	0.53	-0.14	-0.27	-0.47	0.15	-0.18	-0.12	-0.21	-0.42	0.11	-0.82	-0.26		-0.33	0.07	0.09	0.17
Short Long Term Debt	0.67	-0.59	-0.35	-0.79	0.63	0.72	0.63	0.6	-0.59	0.42	-0.14	0.68	-0.67	0.68	0.41	0.73	-0.34	-0.65	0.62	0.79	-0.33		-0.36	-0.43	-0.77
Net Invested Capital	-0.41	0.92	0.34	0.68	-0.59	-0.63	-0.32	-0.34	0.22	0.28	0.05	0.11	0.54	-0.67	-0.17	-0.33	0.62	0.86	-0.15	-0.57	0.07	-0.36		0.9	0.26
Net Working Capital	-0.61	0.93	0.58	0.78	-0.82	-0.78	-0.54	-0.36	0.28	-0.12	0.17	0.03	0.72	-0.76	-0.33	-0.49	0.6	0.93	-0.23	-0.67	0.09	-0.43	0.9		0.41
Capital Stock	-0.78	0.45	0.58	0.77	-0.71	-0.76	-0.76	-0.72	0.49	-0.56	0.63	-0.48	0.77	-0.69	-0.54	-0.81	0.25	0.53	-0.47	-0.81	0.17	-0.77	0.26	0.41

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Novavax

Return On Equity Over Time

Novavax Total Stockholder Equity

Total Stockholder Equity

(681.08 Million)

Novavax reported Total Stockholder Equity of (716.93 Million) in 2023

Based on the latest financial disclosure, Novavax has a Return On Equity of -8.982. This is 62.53% lower than that of the Biotechnology sector and 75.36% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Novavax Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novavax's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics of similar companies.

Novavax is currently under evaluation in return on equity category among its peers.

Novavax ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novavax's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novavax's managers, analysts, and investors.

Environmental

Governance

Social

Novavax Fundamentals

	Return On Equity	-8.98
	Return On Asset	-0.11
	Profit Margin	(0.32) %
	Operating Margin	(1.54) %
	Current Valuation	704.57 M
	Shares Outstanding	160.18 M
	Shares Owned By Insiders	4.37 %
	Shares Owned By Institutions	60.10 %
	Number Of Shares Shorted	41.51 M
	Price To Earning	(1.36) X
	Price To Book	49.52 X
	Price To Sales	1.56 X
	Revenue	983.71 M
	Gross Profit	(156.04 M)
	EBITDA	(487.39 M)
	Net Income	(545.06 M)
	Cash And Equivalents	1.28 B
	Cash Per Share	16.31 X
	Total Debt	229.08 M
	Debt To Equity	8.24 %
	Current Ratio	1.05 X
	Book Value Per Share	(3.29) X
	Cash Flow From Operations	(713.97 M)
	Short Ratio	5.97 X
	Earnings Per Share	(2.18) X
	Target Price	16.0
	Number Of Employees	1.54 K
	Beta	2.09
	Market Capitalization	1.38 B
	Total Asset	1.8 B
	Retained Earnings	(4.82 B)
	Working Capital	(491.25 M)
	Current Asset	287.26 M
	Current Liabilities	76.49 M
	Net Asset	1.8 B

About Novavax Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC